Form 8-K

8-K — Astrana Health, Inc.

Accession: 0001104659-26-092003

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0001083446

SIC: 8742 (SERVICES-MANAGEMENT CONSULTING SERVICES)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2622348d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622348d1_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (tm2622348d1_ex99-2.htm)

GRAPHIC (tm2622348d1_ex99-1img01.jpg)

GRAPHIC (tm2622348d1_ex99-2img001.jpg)

GRAPHIC (tm2622348d1_ex99-2img002.jpg)

GRAPHIC (tm2622348d1_ex99-2img003.jpg)

GRAPHIC (tm2622348d1_ex99-2img004.jpg)

GRAPHIC (tm2622348d1_ex99-2img005.jpg)

GRAPHIC (tm2622348d1_ex99-2img006.jpg)

GRAPHIC (tm2622348d1_ex99-2img007.jpg)

GRAPHIC (tm2622348d1_ex99-2img008.jpg)

GRAPHIC (tm2622348d1_ex99-2img009.jpg)

GRAPHIC (tm2622348d1_ex99-2img010.jpg)

GRAPHIC (tm2622348d1_ex99-2img011.jpg)

GRAPHIC (tm2622348d1_ex99-2img012.jpg)

GRAPHIC (tm2622348d1_ex99-2img013.jpg)

GRAPHIC (tm2622348d1_ex99-2img014.jpg)

GRAPHIC (tm2622348d1_ex99-2img015.jpg)

GRAPHIC (tm2622348d1_ex99-2img016.jpg)

GRAPHIC (tm2622348d1_ex99-2img017.jpg)

GRAPHIC (tm2622348d1_ex99-2img018.jpg)

GRAPHIC (tm2622348d1_ex99-2img019.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622348d1_8k.htm · Sequence: 1

false

0001083446

2026-08-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,

DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the

Securities Exchange Act of 1934

Date of report (Date of earliest event

reported): August 6, 2026

ASTRANA HEALTH, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-37392

95-4472349

(State or Other Jurisdiction

(Commission

(I.R.S. Employer

of Incorporation)

File Number)

Identification No.)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

(626) 282-0288

Registrant’s Telephone Number, Including

Area Code

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

symbol(s)

Name

of each exchange on which registered

Common

Stock, $0.001 par value per share

ASTH

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition.

On August 6, 2026, Astrana Health, Inc. (the “Company”)

issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release

is furnished with this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

The information furnished pursuant to this Item 2.02 to this Current

Report on Form 8-K, including the exhibit, is being “furnished” and, as such, shall not be deemed to be “filed”

for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise

subject to the liabilities of that section, nor shall it be incorporated by reference into any filing under the Securities Act of

1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference

in such filing.

Item 7.01

Regulation FD Disclosure.

The Company has scheduled a conference call and webcast at 2:30 p.m.

Pacific Time/5:30 p.m. Eastern Time on August 6, 2026 to discuss the Company’s financial results for the three and six months ended

June 30, 2026. In addition to the press release, an earnings presentation will be made available on the Company’s investor relations

page at ir.astranahealth.com. A copy of the earnings presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K

and incorporated herein by reference.

The information furnished pursuant to this Item 7.01 to this Current

Report on Form 8-K, including the exhibit, is being “furnished” and, as such, shall not be deemed to be “filed”

for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be incorporated

by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific

reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release of Astrana Health, Inc. Regarding its Financial Results for the Three and Six Months Ended June 30, 2026, dated August 6, 2026.

99.2

Supplemental Data of Astrana Health, Inc., dated August 6, 2026.

104

Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ASTRANA HEALTH, INC.

Date: August 6, 2026

By:

/s/ Brandon K. Sim

Name:

Brandon K. Sim

Title:

Chief Executive Officer and President

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622348d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Astrana Health, Inc. Reports Second Quarter

2026 Results

Company to Host Conference Call on Thursday,

August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET

· Reports revenue of $972.5 million, up 49%

year-over-year, net income of $18.5 million, up 81% year-over-year, and adjusted EBITDA(1) of $68.9 million, up 43% year-over-year

for the three months ended June 30, 2026

· Reports net cash provided by operating activities

of $100.8 million and free cash flow(2) of $92.9 million for the six months ended June 30, 2026

ALHAMBRA, Calif., August 6, 2026 /PRNewswire/

-- Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”)

(NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and

high-value care to all, today announced its consolidated financial results for the second quarter ended June 30, 2026.

“Our second quarter results reflect the

strength of Astrana’s physician-centric, AI-native healthcare operating system and the disciplined execution of our team,”

said Brandon Sim, President and Chief Executive Officer of Astrana Health. “We continue to see accelerating demand from both providers

and payers for our platform, driving strong growth, record-high adjusted diluted EPS, and robust free cash flow generation. Our performance

gives us the confidence to raise our adjusted EBITDA guidance for 2026 even as we reinvest a substantial portion of our first-half outperformance

into attractive growth opportunities that we believe will further strengthen our earnings power over time.”

Financial Highlights for Second Quarter Ended June 30, 2026:

All comparisons are to the three months ended

June 30, 2025 unless otherwise stated.

· Total revenue of $972.5 million, up 49% from $654.8 million

· Care Partners revenue of $932.8 million, up 48% from $631.4 million

· Net income attributable to Astrana of $19.7 million, up 109% from $9.4 million

· Earnings per share (“EPS”) - diluted of $0.40, up 111% from $0.19

· Adjusted EBITDA(1) of $68.9 million, up 43% from $48.1 million

· Adjusted EPS - diluted(3) of $0.80, up 45% from $0.55

Financial Highlights for Six Months Ended June 30, 2026:

All comparisons are to the six months ended

June 30, 2025 unless otherwise stated.

· Total revenue of $1,937.6 million, up 52% from $1,275.2 million

· Care Partners revenue of $1,842.5 million, up 50% from $1,232.4 million

· Net income attributable to Astrana of $34.2 million, up 112% from $16.1 million

· EPS - diluted of $0.69, up 109% from $0.33

· Adjusted EBITDA(1) of $135.2 million, up 60% from $84.5 million

· Adjusted EPS - diluted(3) of $1.54, up 59% from $0.97

· Net cash provided by operating activities of $100.8 million

· Free cash flow(2) of $92.9 million

(1) See “Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin” and

“Use of Non-GAAP Financial Measures” below for additional information.

(2) See reconciliation provided with the condensed consolidated statements of cash flow and “Use of

Non-GAAP Financial Measures” below for additional information.

(3) See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted

EPS - Diluted” and “Use of Non-GAAP Financial Measures” below for additional information.

Recent Operating Highlights

· Daniel Rothman joined as President of Physician Enterprise and Vishal Gupta joined as Senior Vice President

of Enterprise Transformation, further strengthening the executive leadership team as the Company continues to scale its physician-centric,

AI-native operating platform for value-based care.

· Astrana’s affiliated Accountable Care Organizations (“ACOs”) generated $120.4 million

in gross shared savings for the 2024 performance year, and Astrana Care Partners ACO ranked seventh nationwide in net shared savings per

beneficiary in its first performance year.

· Astrana continued to expand its Medicare Advantage footprint, including new agreements in Hawaii and Texas.

The Texas agreement added approximately 3,000 new Medicare Advantage professional-risk lives.

Segment Results for three months ended June 30,

2026:

All comparisons are to the three months ended

June 30, 2025 unless otherwise stated.

Three Months Ended June 30, 2026

(in thousands)

Care

Partners

Care

Delivery

Care

Enablement

Intersegment

Elimination

Corporate

Costs

Consolidated

Total

Total revenues

$ 932,836

$ 74,696

$ 85,598

$ (120,610 )

$ —

$ 972,520

% change vs. prior year quarter

48 %

95 %

109 %

Cost of services

805,469

61,923

51,665

(50,559 )

—

868,498

General and administrative expenses

72,133

14,552

16,158

(70,091 )

21,398

54,150

Depreciation and amortization

12,362

1,188

1,378

—

622

15,550

Total expenses

889,964

77,663

69,201

(120,650 )

22,020

938,198

Income (loss) from operations

$ 42,872

$ (2,967 )

$ 16,397

$ 40 (1)

$ (22,020 )

$ 34,322

% change vs. prior year quarter

(14 )%

(238 )%

* Percentage change of over 500%.

(1) Income from operations for the intersegment elimination represents sublease income between segments. Sublease

income is presented within other income, which is not presented in the table.

2026 Guidance:

Based on the Company’s existing business,

current view of existing market conditions, and assumptions, Astrana is providing the following guidance for total revenue and Adjusted

EBITDA for the three months ending September 30, 2026, updating Adjusted EBITDA guidance for the year ending December 31, 2026,

and reaffirming revenue and free cash flow guidance for the year ending December 31, 2026.

Three Months Ending

September 30, 2026

Year Ending

December 31, 2026

Guidance Range

($ in millions)

Low

High

Low

High

Total revenue

$ 1,000

$ 1,030

$ 3,800

$ 4,100

Adjusted EBITDA

$ 72.5

$ 77.5

$ 255

$ 280

Free cash flow

$ 105

$ 132.5

See “Guidance Reconciliation of Net Income

to EBITDA and Adjusted EBITDA,” “Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow,”

and “Use of Non-GAAP Financial Measures” below for additional information. There can be no assurance that actual amounts will

not be materially higher or lower than these expectations. See “Forward-Looking Statements” below for additional information.

Conference Call and Webcast Information:

Astrana will host a conference call at 2:30 p.m. PT/5:30

p.m. ET today (Thursday, August 6, 2026), during which management will discuss the results of the second quarter ended

June 30, 2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled

conference call time:

U.S. & Canada (Toll-Free):

+1 (877) 858-9810

International (Toll):

+1 (201) 689-8517

The conference call can also be accessed

via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=w7Ip0KQB

An accompanying

slide presentation will be available in PDF format on the “IR Calendar” page of the Company’s website (https://ir.astranahealth.com/news-events/ir-calendar)

after issuance of the earnings release and will be furnished as an exhibit to Astrana’s current report on Form 8-K to be filed

with the SEC, accessible at www.sec.gov.

Those who are unable to attend the live conference

call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

Note About Consolidated Entities

The Company consolidates entities in which it

has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of

the voting rights, and variable interest entities (“VIEs”) in which the Company is the primary beneficiary. Non-controlling

interests represent third party equity ownership interests in the Company’s consolidated entities (including certain VIEs). The

amount of net income or loss attributable to non-controlling interests is disclosed in the Company’s consolidated statements of

income.

About Astrana Health, Inc.

Astrana Health is a physician-centric, AI-powered

healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines

its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive

care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across

the healthcare system.

Today, Astrana

supports more than 20,000 providers and approximately 1.5 million patients in value-based care arrangements through its affiliated provider

networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together,

Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for

all. For more information, visit www.astranahealth.com.

Forward-Looking Statements

This press release contains forward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s guidance

for the quarter ending September 30, 2026 and the year ending December 31, 2026, ability to meet operational goals, ability

to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving

quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing

environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition

strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting

and the Company’s ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views

with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations

and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or

may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties

and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the SEC,

including, without limitation the risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31,

2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statement made by the Company in this release speaks only

as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as

a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations

investors@astranahealth.com

ASTRANA HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

June 30,

2026

December 31,

2025

(Unaudited)

Assets

Current assets

Cash and cash equivalents

$ 400,792

$ 429,474

Receivables, net (including amounts from related parties)

465,080

374,465

Income taxes receivable

—

1,799

Other receivables

24,113

26,385

Prepaid expenses and other current assets

25,857

26,264

Loans receivable

3,318

4,926

Total current assets

919,160

863,313

Non-current assets

Property and equipment, net

62,567

57,332

Intangible assets, net

243,312

270,968

Goodwill

886,995

865,305

Income taxes receivable, net of current portion

26,220

Loans receivable, net of current portion

49,273

48,724

Investments in other entities – equity method

27,805

25,637

Operating lease right-of-use assets

39,194

35,738

Other assets

27,554

25,424

Total non-current assets

1,362,920

1,355,348

Total assets (1)

$ 2,282,080

$ 2,218,661

Liabilities, Mezzanine Deficit, and Stockholders’ Equity

Current liabilities

Accounts payable and accrued expenses

$ 245,860

$ 195,912

Fiduciary accounts payable

3,771

3,524

Income taxes payable

2,082

—

Medical liabilities

415,765

335,705

Operating lease liabilities

8,938

7,809

Current portion of long-term debt

53,848

47,865

Other liabilities

17,375

24,458

Total current liabilities

747,639

615,273

Non-current liabilities

Deferred tax liability

8,795

5,491

Operating lease liabilities, net of current portion

33,975

31,552

Long-term debt, net of current portion and deferred financing costs

882,650

990,904

Other long-term liabilities

10,442

17,107

Total non-current liabilities

935,862

1,045,054

Total liabilities (1)

1,683,501

1,660,327

Mezzanine deficit

Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (“APC”)

(242,261 )

(234,962 )

Stockholders’ equity

Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; and zero shares issued and outstanding as of June 30, 2026 and December 31, 2025

—

Common stock, $0.001 par value per share; 100,000,000 shares authorized, 49,226,943 and 48,885,358 shares issued and outstanding, excluding 10,695,758 and 10,571,011 treasury shares, as of June 30, 2026 and December 31, 2025, respectively

Additional paid-in capital

487,820

470,863

Retained earnings

342,355

308,379

Total stockholders’ equity

830,224

779,291

Non-controlling interests

10,616

14,005

Total equity

840,840

793,296

Total liabilities, mezzanine deficit, and stockholders’ equity

$ 2,282,080

$ 2,218,661

(1) The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated

VIEs. The condensed consolidated balance sheets include (a) total assets of $1,268.9 million and $1,276.5 million as of June 30,

2026 and December 31, 2025, respectively, that can be used only to settle obligations of the Company’s consolidated VIEs and

(b) total liabilities of the consolidated VIEs of $366.9 million and $376.0 million as of June 30, 2026 and December 31,

2025, respectively, for which creditors do not have recourse to the general credit of the Company, the VIE’s primary beneficiary.

These VIE balances do not include $284.6 million of investment in affiliates and $25.1 million of amount due from affiliates as of June 30,

2026 and $152.2 million of investment in affiliates and $58.3 million of amount due from affiliates as of December 31, 2025, as these

are eliminated upon consolidation and not presented within the condensed consolidated balance sheets.

ASTRANA HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)

(UNAUDITED)

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Revenue

Capitation and other revenue, net

$ 972,520

$ 654,808

$ 1,937,620

$ 1,275,196

Operating expenses

Cost of services, excluding depreciation and amortization

868,498

576,839

1,727,855

1,125,900

General and administrative expenses

54,150

50,725

115,888

94,623

Depreciation and amortization

15,550

6,904

31,028

13,752

Total expenses

938,198

634,468

1,874,771

1,234,275

Income from operations

34,322

20,340

62,849

40,921

Other (expense) income

Income (loss) from equity method investments

548

381

2,268

(486 )

Interest expense

(15,997 )

(7,382 )

(32,098 )

(14,690 )

Interest income

5,907

2,336

9,723

4,647

Unrealized gain (loss) on investments

4,732

5,816

(30 )

Other (loss) income

(2,302 )

1,136

(1,640 )

(3,934 )

Total other expense, net

(7,112 )

(3,515 )

(15,931 )

(14,493 )

Income before provision for income taxes

27,210

16,825

46,918

26,428

Provision for income taxes

8,758

6,609

15,335

9,991

Net income

18,452

10,216

31,583

16,437

Net (loss) income attributable to non-controlling interests

(1,287 )

793

(2,592 )

322

Net income attributable to Astrana Health, Inc.

$ 19,739

$ 9,423

$ 34,175

$ 16,115

Earnings per share – basic

$ 0.40

$ 0.19

$ 0.70

$ 0.33

Earnings per share – diluted

$ 0.40

$ 0.19

$ 0.69

$ 0.33

Weighted average shares of common stock outstanding – basic

49,115,835

49,187,885

48,986,953

48,831,265

Weighted average shares of common stock outstanding – diluted

49,778,028

49,470,677

49,418,278

49,162,653

Revenue consisted of the following (in thousands):

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Capitation, net

$ 905,804

$ 614,108

$ 1,798,712

$ 1,198,071

Risk pool settlements and incentives

21,816

15,402

34,302

29,893

Management fee income

13,211

2,577

28,896

4,887

Fee-for-service, net

22,982

17,878

60,813

32,769

Other revenue

8,707

4,843

14,897

9,576

Capitation and other revenue, net

$ 972,520

$ 654,808

$ 1,937,620

$ 1,275,196

ASTRANA HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)

Six Months Ended

June 30,

2026

2025

Cash flows from operating activities

Net income

$ 31,583

$ 16,437

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

31,028

13,752

Amortization of debt issuance cost

2,280

1,740

Share-based compensation

21,682

19,519

Non-cash lease expense

4,131

2,559

Deferred tax

2,734

(1,961 )

Change in fair value of contingent consideration liabilities

(4,820 )

3,351

Other

(6,735 )

560

Changes in operating assets and liabilities, net of business combinations

18,921

51,571

Net cash provided by operating activities

100,804

107,528

Cash flows from investing activities

Payments for business and assets acquisition, net of cash acquired

(3,739 )

—

Purchases of property and equipment

(7,878 )

(4,490 )

Other

2,545

1,019

Net cash used in investing activities

(9,072 )

(3,471 )

Cash flows from financing activities

Dividends paid

(199 )

(6,233 )

Borrowings on debt

—

412,000

Repayment of debt

(103,933 )

(431,357 )

Deferred financing cost

—

(17,241 )

Payment of contingent liabilities

(2,864 )

(3,631 )

Taxes paid from net share settlement of restricted stock

(3,834 )

(5,053 )

Repurchase of treasury shares

(4,364 )

(1,316 )

Other

(4,840 )

Net cash used in financing activities

(120,034 )

(52,808 )

Net (decrease) increase in cash, cash equivalents, and restricted cash

(28,302 )

51,249

Cash, cash equivalents, and restricted cash, beginning of period

434,045

289,101

Cash, cash equivalents, and restricted cash, end of period

$ 405,743

$ 340,350

Supplemental disclosures of cash flow information

Cash paid for income taxes

(1)

$ 4,728

Cash paid for interest

$ 29,348

$ 13,535

Supplemental disclosures of non-cash investing and financing activities

Right-of-use assets obtained in exchange for operating lease liabilities

$ 2,795

$ 7,110

Dividend paid in the form of common stock

$ —

$ 21,935

(1) Following the adoption of ASC 2023-09 "Income Taxes (Topics

740): Improvements to Income Tax Disclosures", cash paid for income taxes is presented net of tax refunds, for the quarterly period

ended June 30, 2026, under Item 1 of the Company’s Quarterly Report on Form 10-Q.

The following table provides a reconciliation

of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total amounts

of cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows (in thousands):

June 30,

2026

December 31,

2025

June 30,

2025

Cash and cash equivalents

$ 400,792

$ 429,474

$ 339,703

Restricted cash (1)

4,951

4,571

647

Total cash, cash equivalents, and restricted cash, end of period shown in the statement of cash flows

$ 405,743

$ 434,045

$ 340,350

(1) Restricted cash is included in other assets on the condensed consolidated balance sheets.

Reconciliation of Net Cash Provided by Operating

Activities to Free Cash Flow

Six Months Ended

June 30,

(in thousands)

2026

2025

Net cash provided by operating activities

$ 100,804

$ 107,528

Purchases of property and equipment

(7,878 )

(4,490 )

Free cash flow

$ 92,926

$ 103,038

Reconciliation of Net Income to EBITDA, Adjusted

EBITDA and Adjusted EBITDA Margin

Set forth below are reconciliations of Net Income

to EBITDA and Adjusted EBITDA, as well as the reconciliations to Adjusted EBITDA margin for the three and six months ended June 30,

2026 and 2025. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.

Three Months Ended

June 30,

Six Months Ended

June 30,

(in thousands)

2026

2025

2026

2025

Net income

$ 18,452

$ 10,216

$ 31,583

$ 16,437

Interest expense

15,997

7,382

32,098

14,690

Interest income

(5,907 )

(2,336 )

(9,723 )

(4,647 )

Provision for income taxes

8,758

6,609

15,335

9,991

Depreciation and amortization

15,550

6,904

31,028

13,752

EBITDA

52,850

28,775

100,321

50,223

(Income) loss from equity method investments

(548 )

(381 )

(2,268 )

486

Other, net

4,800 (1)

7,998 (2)

15,450 (3)

14,257 (4)

Stock-based compensation

11,787

11,709

21,682

19,519

Adjusted EBITDA

$ 68,889

$ 48,101

$ 135,185

$ 84,485

Total revenue

$ 972,520

$ 654,808

$ 1,937,620

$ 1,275,196

Adjusted EBITDA margin

7 %

(1) Other, net, for the three months ended June 30, 2026, relates to post-acquisition integration costs,

non-cash update to the fair value of an equity purchase financing obligation, accruals for non-routine legal matters, and severance.

(2) Other, net, for the three months ended June 30, 2025, relates

to transaction and other costs related to our acquisitions including Prospect, non-cash changes in the fair value of our call option

and collar agreement, and severance.

(3) Other, net, for the six months ended June 30, 2026 relates to an allowance on receivables that the

Company plans to recover from the payer, post-acquisition integration costs, non-cash update to the fair value of an equity purchase financing

obligation, accruals for non-routine legal matters, and severance.

(4) Other, net, for the six months ended June 30, 2025 relates

to debt issuance costs expensed in connection with our Second Amended and Restated Credit Facility, transaction and other costs

related to our acquisitions including Prospect, non-cash changes in the fair values of our call option and collar agreement, and severance.

Reconciliation of Net Income to Adjusted Net

Income Attributable to Astrana and Adjusted EPS - Diluted

Set forth below are reconciliations of net income to adjusted net income

attributable to Astrana as well as the reconciliation to adjusted EPS - diluted for the three and six months ended June 30, 2026

and 2025.

Three Months Ended

June 30,

Six Months Ended

June 30,

(in thousands, except for share and per share data)

2026

2025

2026

2025

Net income

$ 18,452

$ 10,216

$ 31,583

$ 16,437

(Income) loss from equity method investments

(548 )

(381 )

(2,268 )

486

Other, net (1)

4,800

7,998

15,450

14,257

Stock-based compensation

11,787

11,709

21,682

19,519

Amortization of intangible assets attributable to acquisitions

13,806

6,179

27,656

12,442

Tax adjustments

(5,965 )(2)

(4,637 )(3)

(13,490 )(2)

(9,238 )(3)

Adjusted net income attributable to non-controlling interests

(2,561 )(4)

(3,715 )(5)

(4,489 )(4)

(6,032 )(5)

Adjusted net income attributable to Astrana Health, Inc.

$ 39,771

$ 27,369

$ 76,124

$ 47,871

Weighted average shares of common stock outstanding – diluted

49,778,028

49,470,677

49,418,278

49,162,653

Adjusted earnings per share - diluted

$ 0.80

$ 0.55

$ 1.54

$ 0.97

(1) The components of other, net, as set forth in the table above, are described in the footnotes to the table

under “Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin”. Please see the footnotes to such

table for additional information.

(2) Tax adjustments for the three and six months ended June 30, 2026, includes the tax effect for, at

a 27.4% statutory blended tax rate, the adjustments made to net income of $8.2 million and $17.0 million, respectively, partially offset

by 162(m) impact of $2.2 million and $3.5 million, respectively.

(3) Tax adjustments for the three and six months ended June 30, 2025, includes the tax effect for, at

a 27.1% statutory blended tax rate, the adjustments made to net income of $6.9 million and $12.7 million, respectively, partially offset

by 162(m) impact of $2.3 million and $3.4 million, respectively.

(4) Includes net loss attributable to non-controlling interests ("NCI") of $1.3 million and $2.6

million, respectively, offset by adjustments attributable to NCI of $3.8 million and $7.1 million, respectively, for the three and six

months ended June 30, 2026.

(5) Includes net income attributable to NCI of $0.8 million and $0.3 million, respectively, as well as adjustments

attributable to NCI of $2.9 million and $5.7 million, respectively, for the three and six months ended June 30, 2025.

Guidance Reconciliation of Net Income to

EBITDA and Adjusted EBITDA

Year Ending

December 31, 2026

Guidance Range

(in thousands)

Low

High

Net income

$ 59,000

$ 74,000

Interest expense

49,000

53,000

Provision for income taxes

38,000

44,000

Depreciation and amortization

65,000

EBITDA

211,000

236,000

Income from equity method investments

(4,000 )

Other, net

9,000

Stock-based compensation

39,000

Adjusted EBITDA

$ 255,000

$ 280,000

The Company has not provided a quantitative reconciliation

of EBITDA and Adjusted EBITDA for the three months ending September 30, 2026 to the most comparable GAAP measure on a forward-looking

basis within this press release because the Company is unable, without unreasonable efforts, to provide reconciling information with respect

to certain line items that cannot be calculated for the three month period. These items, which could materially affect the computation

of forward-looking GAAP net income, are inherently uncertain and depend on various factors, some of which are outside of the Company’s

control.

Guidance Reconciliation of Net Cash Provided

by Operating Activities to Free Cash Flow

Year Ending

December 31, 2026

Guidance Range

(in thousands)

Low

High

Net cash provided by operating activities

$ 125,000

$ 145,000

Cash used in purchases of property and equipment

(20,000 )

(12,500 )

Free cash flow

$ 105,000

$ 132,500

Use of Non-GAAP Financial Measures

This press release contains the non-GAAP financial

measures EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana, and adjusted EPS – diluted,

of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”)

is net income. This press release also contains the non-GAAP financial measure free cash flow, of which the most directly comparable financial

measure presented in accordance with U.S. GAAP is net cash provided by operating activities. These measures are not in accordance with,

or alternatives to, GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. We use Adjusted

EBITDA, Adjusted EBITDA margin, adjusted EPS – diluted, and free cash flow as supplemental performance measures of our operations,

for financial and operational decision-making, and as supplemental means of evaluating period-to-period comparisons on a consistent basis

and, for free cash flow, to reflect the cash flow trends in our business. Adjusted EBITDA is calculated as earnings before interest expense,

interest income, income taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring

and non-cash transactions, and stock-based compensation. We define Adjusted EBITDA margin as Adjusted EBITDA over total revenue. Adjusted

net income attributable to Astrana is calculated as net income, excluding income or loss from equity method investments, non-recurring

and non-cash transactions, stock-based compensation, amortization of intangible assets attributable to acquisitions, certain tax adjustments,

and amounts related to net income or loss attributable to non-controlling interests. We define adjusted EPS – diluted as adjusted

net income attributable to Astrana over weighted average shares of common stock outstanding – diluted. We define free cash flow

as net cash provided by operating activities minus cash used in purchases of property and equipment.

We believe the presentation of these non-GAAP

financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance

of the business activities without having to account for differences recognized because of non-core or non-recurring financial information.

When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful

understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as

a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial

measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate

EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana, adjusted EPS – diluted, and free cash

flow differently, limiting the usefulness of these measures for comparative purposes. To the extent this press release contains historical

or future non-GAAP financial measures, we have provided corresponding GAAP financial measures for comparative purposes. The reconciliations

between certain GAAP and non-GAAP measures are provided above.

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: tm2622348d1_ex99-2.htm · Sequence: 3

Exhibit 99.2

August 2026 Second Quarter 2026 Earnings Supplement

2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, est imates of our total addressable market, our ability to successfully complete and realize the benefits of anticipated acquisit ion s, integration of acquired companies and any projections of earnings, revenue, EBITDA, Adjusted EBITDA, adjusted EPS – diluted, fre e cash flow or other financial items, such as the Company's projected capitation and future liquidity, as well as statements reg arding the material weakness in internal control over financial reporting and the Company’s ability to remediate such material weakn ess in a timely manner and may be identified by the use of forward - looking terms such as “anticipate,” “could,” “can,” “may,” “migh t,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “plan,” “envision,” “intend,” “continue,” “targ et, ” “seek,” “will,” “would,” and the negative of such terms, other variations on such terms or other similar or comparable word s, phrases or terminology. Forward - looking statements reflect current views with respect to future events and financial performance and theref ore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual re sul ts. Actual results may also vary materially from forward - looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the U.S. Securities and Exchange Com mission (the “SEC”), including without limitation the risk factors discussed in the Company’s last Annual Report on Form 10 - K an d subsequent quarterly reports on Form 10 - Q filed with the SEC. Because the factors referred to above could cause actual results or outcomes to differ materially from those expressed or imp lie d in any forward - looking statements, you should not place undue reliance on any such forward - looking statements. Any forward - looking statements speak only as of the date of this presentation and, unless legally required, the Company does not undertak e a ny obligation to update any forward - looking statement, as a result of new information, future events or otherwise. This presentation may contain statistics and other data that in some cases has been obtained from or compiled from informatio n m ade available by third - party service providers. The Company makes no representation or warranty, express or implied, with respec t to the accuracy, reasonableness or completeness of such information. Use of Non - GAAP Financial Measures This presentation contains the non - GAAP financial measures EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana , and adjusted EPS – diluted of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”) is net income. This presentation also contains the non - GA AP financial measure free cash flow, of which the most directly comparable financial measure presented in accordance with U.S GAAP is net cash provided by operating activities. These measures are not in accordance with, or alternatives to, GAAP, and m ay be calculated differently from similar non - GAAP financial measures used by other companies. The Company uses Adjusted EBITDA, Adjusted EBITDA margin, adjusted EPS – diluted, and free cash flow as supplemental performance measures of our operations, for f inancial and operational decision - making, and as supplemental means of evaluating period - to - period comparisons on a consistent basis, and, for free cash flow, to reflect the cash flow trends in our business. Adjusted EBITDA is calculated as earnings be for e interest expense, interest income, income taxes, depreciation, and amortization, excluding income or loss from equity metho d investments, non - recurring and non - cash transactions, stock - based compensation, and, for periods on or prior to December 31, 202 3, APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised the calculati on for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more r efl ective of its business. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue. Adjusted net income attributable to Astrana is calculated as net income, excluding income or loss from equity method investments, non - recurring and non - cash transactions, stock - based compensation, amortization of intangible assets attributable to acquisitions, certain tax adjustments, and amounts related to net income or loss attributable to non - controlling interests. The Company defines adjusted E PS - diluted as adjusted net income attributable to Astrana over weighted average shares of common stock outstanding - diluted. The Company defines free cash flow as net cash provided by operating activities minus cash used in purchases of property and equ ipment. The Company believes the presentation of these non - GAAP financial measures provides investors with relevant and useful informati on, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non - core or non - recurring financial information. When GAAP financial measures are viewed in co njunction with non - GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance. In addition, these non - GAAP financial measures are among those indicators the Company uses as a b asis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non - GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other com pan ies may calculate EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana , adjusted EPS – diluted, and free cash flow differently, limiting the usefulness of these measures for comparative purposes. To the extent th is Presentation contains historical or future non - GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non - GAAP measures is provided in the Appendix. The Company has not provided a quantitative reconciliation of applicable non - GAAP measures, such as the projected adjusted EBITD A to the most comparable GAAP measure, such as net income, on a forward - looking basis within this presentation because the Company is unable, without unreasonable efforts, to provide reconciling information with respect to certain line items that c ann ot be calculated. These items, which could materially affect the computation of forward - looking GAAP net income, are inherently uncertain and depend on various factors, some of which are outside of the Company’s control. JZ1

3 Q2 2026 Financial Results 49% 3 $972.5 Revenue 45% 3 $0.80 Adj. EPS – Diluted 2 10% 5 $92.9 5 YTD Free Cash Flow 4 Second Quarter 2026 Performance Highlights $ in millions, except for per share information 1. See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non - GAAP Financial Measures” slides for more info rmation. 2. See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS – Diluted” and “Use of Non - GAAP Financial Measures” slides for more information. 3. All comparisons are to the three months ended June 30, 2025 unless otherwise stated. 4. See “Reconciliation and Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow” and “Use of N on - GAAP Financial Measures” slides for more information. 5. Free cash flow is provided for the six months ended June 30, 2026 and compared to the six months ended June 30, 2025. 43% 3 $68.9 Adj. EBITDA 1 109% 3 $19.7 NI attr. to ASTH MO1 TB2 JZ3 JZ4 AS5

4 FY 2026 Guidance Range 2,3,4 Actual FY 2025 Results $3,800 - $4,100 $3,181.8 Total Revenue $255 - $280 $205.4 Adjusted EBITDA 2 $105 - $132.5 $104.5 Free Cash Flow 3 Q2 2026 Financial Results 1 $972.5 Revenue $68.9 Adjusted EBITDA 2 $92.9 YTD Free Cash Flow 3 1. Q2 2026 Financial Results are provided for the three months ended June 30, 2026 except for free cash flow, which is provided for the six months ended June 30, 2026. 2. See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA,” “Guidance Reconciliation of Net Income to EBITDA and Adjust ed EBITDA” and “Use of Non - GAAP Financial Measures” slides for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward - Looking Stateme nts” on slide 2. 3. See “ Reconciliation and Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow ” and “Use of Non - GAAP Financial Measures” slides for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward - Looking Statements” on slide 2. 4. Raised Adjusted EBITDA guidance to reflect broad - based outperformance across the business. $ in millions FY2026 GuidanceDH1 JZ2 JZ3 AS4

5 Growth Sustainably growing membership to bring better care to more Americans Astrana now serves approximately 1.5 million patients in value - based arrangements Approximately 1.2 million m embers in our Care Partners segment Growth Second Quarter 2026 Highlights and Recent Updates Operating Leverage Driving operating leverage across our business through our Care Enablement suite On track to achieve high end of $12 - 15M synergy range related to Prospect Continued development and deployment of proprietary AI - enabled tools across clinical workflows and administrative processes, leading to 210 bps improvement in G& A as a percentage of revenue year over year ( 5.6 % in Q2 2026, 7.7% in Q2 2025) Risk Progression Increasing alignment through total cost of care responsibility in value - based arrangements 81 % of Q2 2026 capitation revenue from full - risk arrangements Continued prudent shift toward full - risk , accountable care contracts Outcomes and Cost Achieving superior patient outcomes while managing cost Medical cost trends across both Prospect and core Astrana remained firmly within expectations for the quarter Strong engagement in Annual Wellness Visits, supporting earlier intervention and improved care coordination; >500k automated member interactions per month JZ1 AS2 AS3 AS4

6 Projected Full - risk Partial - risk Members by Risk Arrangement 2 35% 47% 73% 76% 81% 81% 100% 65% 53% 27% 24% 19% 19% 2021 2022 2023 2024 2025 Q2 2026 2026 E 42% 43% 58% 57% Q2 2026 2026 E Capitated Revenue by Risk Arrangement 1 Our partial - risk membership presents an embedded opportunity for increased platform value and risk alignment. We succeed in these contracts by continuing to drive positive patient outcomes. 1. Revenue by risk arrangement represents capitation revenue only. 2. Members by risk arrangement represent Care Partners membership only. 3. Revenue for the quarter ended June 30, 2026. 4. 2026 E based on June 2026 forecast. 5. Members by risk arrangement as of June 30, 2026. Prudently transitioning to full - risk contracts to better align incentives around patient outcomes and improve unit economics 2026 E 4 2026 E 4 Q2 2026 3 Q2 2026 5AS1

7 93% 2% 1% 3% Capitation, net Risk Pool Settlements & Incentives Management Fee Income Fee-for-service, net Other Income Revenue by Type 1 61% 27% 9% 3% Medicare Medicaid Commercial Other Third Parties Revenue By Payer Type 1 81% 19% Full-risk Partial-risk Revenue by Risk Arrangement 1,2 42% 58% Full-risk Partial-risk Members by Risk Arrangement 3 Our Value - Based Care Business is Diverse 1% 1. Revenue for the quarter ended June 30, 2026. 2. Revenue by risk arrangement represents capitation revenue only. 3. Members by risk arrangement represent Care Partners membership only as of June 30, 2026.AH1 AH2AS3

8 Revenue ($ in millions) Adj. EBITDA ($ in millions) $561 $687 $774 $1,144 $1,387 $2,035 $3,182 2019 2020 2021 2022 2023 ~32% CAGR 2024 $54.2 $102.8 $133.5 $140.0 $146.6 $170.4 $205.4 2019 2020 2021 2022 2023 2024 ~26% CAGR 2025 $3,800 - $4,100 $255 - $280 2026E 2026E 2025 Astrana grows profitably across all market conditions Note: For more information, see “Reconciliation of Net Income to EBITDA and Adjusted EBITDA”, “Guidance Reconciliation of Net In come to EBITDA and Adjusted EBITDA”, and “Use of Non - GAAP Financial Measures“ slides for more information. JZ1 AS2

9 Quarter over Quarter Segment Revenue Revenue $ in millions Q2 2025 Q3 2025 Q4 2025 Q1 2026 Care Partners High - performing network of aligned providers $ 897 .7 $892.5 Care Delivery High - quality system of employed providers $38.4 $86.9 $92.1 Care Enablement Full - stack tech, clinical, and operations platform $ 40 .9 $ 87 .3 $78.9 Inter - company $(55. 9 ) $(115.9) $(112.9) Total $654.8 $956. 0 $950.5 $909.7 $85.1 $87.7 $(117.4) $965.1 $631.4 Note: Numbers may not total due to rounding. Certain amounts disclosed in the prior periods have been recast to conform to th e c urrent period presentation. Specifically, segments are presented net of intrasegment eliminations. Q2 2026 $ 932.8 $ 74.7 $ 85.6 $(120.6) $ 972.5

10 Selected Financial Results

11 Three Months Ended June 30, 2025 2026 $ in thousands, except per share data Revenue 614,108 $ 905,804 $ Capitation, net 15,402 21,816 Risk pool settlements and incentives 2,577 13,211 Management fee income 17,878 22,982 Fee - for - service, net 4,843 8,707 Other revenue 654,808 972,520 Total revenue 634,468 938,198 Total expenses 20,340 34,322 Income from operations 10,216 $ 18,452 $ Net income 793 (1,287) Net ( loss ) income attributable to non - controlling interests 9,423 $ 19,739 $ Net income attributable to Astrana Health, Inc. 0.19 $ 0.40 $ Earnings per share – diluted 28,775 $ 52,850 $ EBITDA 1 48,101 $ 68,889 $ Adjusted EBITDA 1 0.55 $ 0.80 $ Adjusted EPS – Diluted 2 Summary of Selected Financial Results 1. See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non - GAAP Financial Measures” slides for more inform ation. 2. See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS – Diluted” and “Use of Non - GAA P Financial Measures” slides for more information. TB1 TB2 TB3 TB4 TB5

12 Consolidated Total Corporate Costs Intersegment Elimination Care Enablement Care Delivery Care Partners $ in thousands 972,520 - (120,610) 85,598 74,696 932,836 $ Total revenues 109% 95% 48% % change vs prior year quarter 868,498 - (50,559) 51,665 61,923 805,469 Cost of services 54,150 21,398 (70,091) 16,158 14,552 72,133 General and administrative expenses 15,550 622 - 1,378 1,188 12,362 Depreciation and amortization 938,198 22,020 (120,650) 69,201 77,663 889,964 Total expenses 34,322 (22,020) 40 1 16,397 (2,967) 42,872 $ Income (loss) from operations *2 (238)% (14)% % change vs prior year quarter For the three months ended June 30 , 2026 Segment Results 1. Income from operations for the intersegment elimination represents sublease income between segments. Sublease income is prese nte d within other income which is not presented in the table. 2. Percentage change of over 500% TB1TB2

13 $ Change 12/31/2025 6/30/2026 $ in millions $(28.7) $429.5 $400.8 Cash and cash equivalents 1 $(76.5) $248.0 $171.5 Working capital $47.5 $793.3 $840.8 Total stockholders’ equity Balance Sheet Highlights 1. Excluding restricted cash and marketable securities. TB1 TB2

14 1 . The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue .; 2 . Other, net, for the three months ended June 30 , 2026 relates to post - acquisition integration costs, non - cash update to the fair value of an equity purchase financing obligation, accrual for non - routine legal matters, and severance .; 3 . Other, net for the three months ended June 30 , 2025 relates to transaction and other costs related to our acquisitions including Prospect, non - cash changes in the fair value of our call option and collar agreement, and severance . Three Months Ended June 30, 2025 2026 $ in thousands 10,216 $ 18,452 $ Net Income 7,382 15,997 Interest expense (2,336) (5,907) Interest income 6,609 8,758 Provision for income taxes 6,904 15,550 Depreciation and amortization 28,775 52,850 EBITDA (381) (548) Income from equity method investments 7,998 3 4,800 2 Other, net 11,709 11,787 Stock - based compensation 48,101 7% $ 68,889 7% $ Adjusted EBITDA Adjusted EBITDA margin 1 Reconciliation of Net Income to EBITDA & Adjusted EBITDA TB1TB2 TB3 MO4

15 Year Ended TTM Ended For the twelve months ended 2019 2020 2021 2022 2023 2024 2025 June 30, 2026 $ in millions 15.8 $ 122.1 $ 46.1 $ 45.7 $ 57.8 $ 49.9 $ 24.1 $ 39.2 $ Net Income 4.7 9.5 5.4 7.9 16.1 33.1 50.0 67.3 Interest expense (2.0) (2.8) (1.6) (2.0) (14.2) (14.5) (12.2 ) (17.2) Interest income 10.0 56.3 31.7 40.9 32.0 30.9 15.5 20.9 Provision for income taxes 18.3 18.4 17.5 17.5 17.7 27.9 45.7 63.0 Depreciation and amortization 46.8 203.5 99.1 110.1 109.5 127.3 123.1 173.2 EBITDA 1 2.9 (0.3) 9 5.3 9 (5.7) 9 (5.1) (4.5) (1.7) ( 4.5) (Income) loss from equity method investments - - (2.2) - - - - - Gain on sale of equity method investment 2.0 10 (0.5) 7 (1.7) 7 3.3 6 6.2 5 13.0 4 45.4 3 46.6 2 Other, net 0.9 3.4 6.7 16.1 22.0 34.5 38.6 40.8 Stock - based compensation 1.5 (103.3) 9 26.4 9 16.2 9 14.0 - - - APC excluded assets costs 54.2 $ 102.8 $ 133.5 $ 140.0 $ 146.6 $ 170.4 $ 205.4 $ 256.1 $ Adjusted EBITDA 1 560.6 $ 687.2 $ 773.9 $ 1,144.2 $ 1,386.7 $ 2,034.5 $ 3,181.8 $ 3,844.2 $ Net Revenue 10% 15% 17% 12% 11% 8% 6% 7 % Adjusted EBITDA Margin 8 Reconciliation of Net Income to EBITDA & Adjusted EBITDA (continued) 1 . See “Use of Non - GAAP Financial Measures” slide for more information .; 2 . Other, net, for TTM ended June 30 , 2026 , relates to an allowance on receivables that the Company plans to recover from the payer, post - acquisition integration costs, accruals for non - routine legal matters including $ 13 . 0 million for a legal matter with a provider associated with CFC HP, transaction and other costs related to our acquisitions including Prospect, non - cash changes related to the change in the fair value of an equity purchase finance obligation, our call option and collar agreement, and severance fees incurred .; 3 . Other, net, for the year ended December 31 , 2025 , relates to $ 13 . 0 million for a legal matter with a provider associated with CFC HP, transaction and other costs related to our acquisitions including $ 25 . 9 million for Prospect, debt issuance costs incurred in connection with our Second Amended and Restated Credit Facility, and severance fees incurred, partially offset by employer retention tax credits related to COVID - 19 relief .; 4 . Other, net for the year ended December 31 , 2024 relates to transaction costs incurred for our investments and tax restructuring fees, anticipated recoveries from one time losses relating to third party payer payments associated with the CHS transaction, financial guarantee via a letter of credit that we provided in support of two local provider - led ACOs, reimbursement from a related party of the Company for taxes associated with the December 2023 Excluded Assets Spin - off, non - cash gain on debt extinguishment related to one of our promissory note payables, non - cash realized loss from sale of one of our marketable equity securities, non - cash changes related to change in the fair value of our call option, our financing obligation to purchase the remaining equity interests in one of our investments, our contingent liabilities, and the Company’s collar agreement .; 5 . Other, net for the year ended December 31 , 2023 consists of nonrecurring transaction costs and tax restructuring fees incurred, non - cash changes in the fair value of our financing obligation to purchase the remaining equity interests, contingent liabilities, and the Company’s collar agreement, and excise tax related to a nonrecurring buyback of the Company’s stock from APC .; 6 . Other, net for the year ended December 31 , 2022 consists of one - time transaction costs incurred and non - cash changes in the fair value of our financing obligation to purchase the remaining equity interests and contingent considerations .; 7 . Other, net for the years ended December 31 , 2021 and 2020 relate to COVID - 19 relief payments recognized in 2021 and 2020 .; 8 . The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue .; 9 . Certain APC minority interests where APC owns the asset but not the right to the dividends is reclassified from APC excluded asset costs to income from equity method investments .; 10 . Other, net for the year ended December 31 , 2019 is related to goodwill impairment . JZ1 JZ2 MO3 JZ4 JZ5

16 Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted Three Months Ended June 30, 2025 2026 $ in thousands, except for share and per share data 10,216 $ 18,452 $ Net income (381) (548) Income from equity method investments 7,998 4,800 Other, net 1 11,709 11,787 Stock - based compensation 6,179 13,806 Amortization of intangible assets attributable to acquisitions (4,637) 3 (5,965) 2 Tax adjustments (3,715) 5 (2,561) 4 Adjusted net income attributable to non - controlling interests 27,369 $ 39,771 $ Adjusted net income attributable to Astrana Health, Inc. 6 49,470,677 49,778,028 Weighted average shares of common stock outstanding – diluted 0.55 $ 0.80 $ Adjusted earnings per share – diluted 6 1 . The components of other, net, as set forth in the table above, are described in the footnotes to the table under “Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin” . Please see the footnotes to such table for additional information .; 2 . Tax adjustments for the three months ended June 30 , 202 6 , includes the tax effect for, at a 27 . 4 % statutory blended tax rate, the adjustments made to net income of $ 8 . 2 million, partially offset by 162 (m) impact of $ 2 . 2 million .; 3 . Tax adjustments for the three months ended June 30 , 2025 , includes the tax effect for, at a 27 . 1 % statutory blended tax rate, the adjustments made to net income of $ 6 . 9 million, partially offset by 162 (m) impact of $ 2 . 3 million .; 4 . Includes net loss attributable to non - controlling interests ("NCI") of $ 1 . 3 million, offset by adjustments attributable to NCI of $ 3 . 8 million, for the three months ended June 30 , 2026 .; 5 . Includes net income attributable to NCI of $ 0 . 8 million, as well as adjustments attributable to NCI of $ 2 . 9 million, for the three months ended June 30 , 2025 . ; 6 . See “Use of Non - GAAP Financial Measures” slide fo r more information . MO1 TB2 MO3 JZ4

17 Guidance 1 Actual Results $ in thousands Year Ending December 31, 2026 Six Months Ended June 30, 2025 Year Ended December 31, 2025 Six Months Ended June 30, 2026 High Low 145,000 $ 125,000 $ 107,528 $ 114,597 $ 100,804 $ Net cash provided by operating activities (12,500) (20,000) (4,490) (10,106) (7,878) Cash used in purchases of property and equipment 132,500 $ 105,000 $ 103,038 $ 104,491 $ 92,926 $ Free cash flow 2 1. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward - Looki ng Statements” on slide 2. 2. See “Use of Non - GAAP Financial Measures” slide for more information. Reconciliation and Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow MO1 JZ2

18 . Guidance Reconciliation of Net Income to EBITDA & Adjusted EBITDA 1. Note: See “Use of Non - GAAP Financial Measures” slide for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward - Looki ng Statements” on slide 2. 2026 Guidance Range High Low $ in thousands 74,000 $ 59,000 $ Net Income 53,000 49,000 Interest expense 44,000 38,000 Provision for income taxes 65,000 65,000 Depreciation and amortization 236,000 211,000 EBITDA (4,000) (4,000) Income from equity method investments 9,000 9,000 Other, net 39,000 39,000 Stock - based compensation 280,000 $ 255,000 $ Adjusted EBITDAAS1

Investor Relations investors@astranahealth.com

GRAPHIC

Filename: tm2622348d1_ex99-1img01.jpg · Sequence: 7

Binary file (30028 bytes)

Download tm2622348d1_ex99-1img01.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img001.jpg · Sequence: 8

Binary file (109873 bytes)

Download tm2622348d1_ex99-2img001.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img002.jpg · Sequence: 9

Binary file (327610 bytes)

Download tm2622348d1_ex99-2img002.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img003.jpg · Sequence: 10

Binary file (98791 bytes)

Download tm2622348d1_ex99-2img003.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img004.jpg · Sequence: 11

Binary file (111059 bytes)

Download tm2622348d1_ex99-2img004.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img005.jpg · Sequence: 12

Binary file (182748 bytes)

Download tm2622348d1_ex99-2img005.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img006.jpg · Sequence: 13

Binary file (133183 bytes)

Download tm2622348d1_ex99-2img006.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img007.jpg · Sequence: 14

Binary file (99885 bytes)

Download tm2622348d1_ex99-2img007.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img008.jpg · Sequence: 15

Binary file (94475 bytes)

Download tm2622348d1_ex99-2img008.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img009.jpg · Sequence: 16

Binary file (105119 bytes)

Download tm2622348d1_ex99-2img009.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img010.jpg · Sequence: 17

Binary file (126090 bytes)

Download tm2622348d1_ex99-2img010.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img011.jpg · Sequence: 18

Binary file (114226 bytes)

Download tm2622348d1_ex99-2img011.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img012.jpg · Sequence: 19

Binary file (98418 bytes)

Download tm2622348d1_ex99-2img012.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img013.jpg · Sequence: 20

Binary file (66366 bytes)

Download tm2622348d1_ex99-2img013.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img014.jpg · Sequence: 21

Binary file (106537 bytes)

Download tm2622348d1_ex99-2img014.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img015.jpg · Sequence: 22

Binary file (185803 bytes)

Download tm2622348d1_ex99-2img015.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img016.jpg · Sequence: 23

Binary file (152918 bytes)

Download tm2622348d1_ex99-2img016.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img017.jpg · Sequence: 24

Binary file (94166 bytes)

Download tm2622348d1_ex99-2img017.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img018.jpg · Sequence: 25

Binary file (101153 bytes)

Download tm2622348d1_ex99-2img018.jpg

GRAPHIC

Filename: tm2622348d1_ex99-2img019.jpg · Sequence: 26

Binary file (123854 bytes)

Download tm2622348d1_ex99-2img019.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 28

v3.26.1

Cover

Aug. 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 06, 2026

Entity File Number

001-37392

Entity Registrant Name

ASTRANA HEALTH, INC.

Entity Central Index Key

0001083446

Entity Tax Identification Number

95-4472349

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1668 S. Garfield Avenue

Entity Address, Address Line Two

2nd Floor

Entity Address, City or Town

Alhambra

Entity Address, State or Province

Entity Address, Postal Zip Code

91801

City Area Code

626

Local Phone Number

282-0288

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.001 par value per share

Trading Symbol

ASTH

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration